Advisors Asset Management Inc. Has $2.39 Million Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Advisors Asset Management Inc. raised its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 17.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,195 shares of the company's stock after acquiring an additional 1,046 shares during the quarter. Advisors Asset Management Inc.'s holdings in Medpace were worth $2,390,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Thrivent Financial for Lutherans lifted its stake in Medpace by 738.0% during the fourth quarter. Thrivent Financial for Lutherans now owns 120,928 shares of the company's stock valued at $40,176,000 after purchasing an additional 106,498 shares during the last quarter. Polen Capital Management LLC lifted its position in shares of Medpace by 8.4% during the 4th quarter. Polen Capital Management LLC now owns 16,223 shares of the company's stock valued at $5,390,000 after acquiring an additional 1,259 shares during the last quarter. GWN Securities Inc. bought a new stake in shares of Medpace during the 4th quarter worth $278,000. Corient Private Wealth LLC grew its holdings in shares of Medpace by 86.1% in the 4th quarter. Corient Private Wealth LLC now owns 2,380 shares of the company's stock worth $791,000 after acquiring an additional 1,101 shares during the last quarter. Finally, Natixis Advisors LLC lifted its holdings in shares of Medpace by 27.1% during the fourth quarter. Natixis Advisors LLC now owns 14,287 shares of the company's stock valued at $4,747,000 after purchasing an additional 3,042 shares during the last quarter. Institutional investors own 77.98% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on MEDP shares. Robert W. Baird lifted their price target on Medpace from $354.00 to $362.00 and gave the stock a "neutral" rating in a research note on Monday, January 27th. Leerink Partners started coverage on shares of Medpace in a research report on Monday. They issued a "market perform" rating and a $330.00 target price on the stock. Finally, Leerink Partnrs raised shares of Medpace to a "hold" rating in a research note on Monday. Nine research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average target price of $376.30.

Medpace Stock Down 2.1 %

Shares of NASDAQ:MEDP traded down $6.86 during trading on Wednesday, reaching $317.65. 549,067 shares of the company traded hands, compared to its average volume of 290,505. Medpace Holdings, Inc. has a 1-year low of $302.01 and a 1-year high of $459.77. The firm has a market cap of $9.68 billion, a P/E ratio of 25.15, a price-to-earnings-growth ratio of 3.81 and a beta of 1.47. The firm has a fifty day simple moving average of $337.16 and a 200 day simple moving average of $339.57.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, beating analysts' consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. As a group, research analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.